CLIENTS PARTICIPANTS
Bioactive Ingredients Bioactive Ingredients

At INQUIS Clinical Research, we are proud to support our clients’ product development. With research to determine effect and mechanism of action, we ensure our clients are well-equipped with the data they need to determine product development and strategic direction.

Bioactive Ingredients
Areas of Expertise
Efficacy

At INQUIS Clinical Research, we can determine the efficacy of your bioactive ingredient by examining:

  • Changes in metabolic health
  • Changes in cardiovascular disease risk factors
  • Glucose and insulin responses
  • Markers of inflammation

 

Contact us to learn how we can help you achieve your clinical research objectives.

Publications

Jenkins AL, Kacinik V, Lyon M, Wolever TMS. Effect of adding the novel fiber, PGX®, to commonly consumed foods on glycemic response, glycemic index and GRIP: a simple and effective strategy for reducing post prandial blood glucose levels – a randomized, controlled trial. Nutr J 2010;9:58.

Read More

Vuksan V, Whitham D, Sievenpiper JL, Jenkins AL, Rogovik AL, Bazinet RP, Vidgen E, Hanna A. Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial. Diabetes Care 2007;30(11):2804-10.

Read More
Safety

Demonstrating the safety of bioactive ingredients is paramount to supporting claims and achieving product approval.  At INQUIS Clinical Research, we are experienced in designing and executing studies that look at important safety indicators such as liver enzymes and markers of kidney function to ensure that your product is tested properly and safely before going to market.

Contact us to learn how we can help you achieve your clinical research objectives.

Publications

Jenkins AL, Morgan LM, Bishop J, Jovanovski E, Jenkins DJA, Vuksan V. Co-administration of a konjac-based fibre blend and American ginseng (Panax quinquefolius L.) on glycaemic control and serum lipids in type 2 diabetes: a randomized controlled, cross-over clinical trial. Eur J Nutr 2018;57(6):2217-2225. doi: 10.1007/s00394-017-1496-x.

Read More

Vuksan V, Xu ZZ, Jovanovski E, Jenkins AL, Beljan-Zdravkovic U, Sievenpiper JL, Mark Stavro P, Zurbau A, Duvnjak L, Li MZC. Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial. Eur J Nutr. 2018. doi: 10.1007/s00394-018-1642-0.

Read More

Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A, Carleton AJ, Ha V, Di Buono M, Jenkins AL, Leiter LA, Wolever TM, Don-Wauchope AC, Beyene J, Kendall CW, Jenkins DJ. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr. 2014;68(4):416-23. doi: 10.1038/ejcn.2014.8.

Read More

Vuksan V, Whitham D, Sievenpiper JL, Jenkins AL, Rogovik AL, Bazinet RP, Vidgen E, Hanna A. Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial. Diabetes Care 2007;30(11):2804-10.

Read More
Tolerance

Determining whether a food or ingredient is digested can be established by appearance of glucose in the blood and the stimulation of insulin response. Our team of researchers is experienced in determining digestibility, as well as bioavailability and bioequivalency.

At INQUIS Clinical Research, our team of researchers can develop and execute both acute and long term research study designs to determine the gastrointestinal tolerance of foods and ingredients, sweeteners and fibers.

Contact us to learn how we can help you achieve your clinical research objectives.

Publications

Wolever TMS, Chiasson J-L, Josse RG, Leiter LA, Maheux P, Rabasa-Lhoret R, Rodger NW, Ryan EA. Effects of changing the amount and source of dietary carbohydrates on symptoms and dietary satisfaction over a 1-year period in subjects with type 2 diabetes: Canadian trial of carbohydrates in diabetes (CCD). Can J Diab 2017;41:164-76.

Read More

Wolever TMS, van Klinken BJW, Bordenave N, Kaczmarczyk M, Jenkins AL, Chu YF, Harkness L. Reformulating cereal bars: high resistant starch reduces in vitro digestibility but not in vivo glucose or insulin response; whey protein reduces glucose but disproportionately increases insulin. Am J Clin Nutr 2016;104:(4)

Read More

Rahat-Rozenbloom S, Fernandes J, Cheng J, Wolever TMS. Acute increases in serum colonic short-chain fatty acids elicited by inulin do not increase GLP-1 or PYY responses but may reduce ghrelin in lean and overweight humans. Eur J Clin Nutr 2017;71(8):953-958. doi: 10.1038/ejcn.2016.249.

Read More

Belcheva A, Irrazabal T, Robertson SJ, Streutker C, Maughan H, Rubino S, Moriyama EH, Copeland JK, Surendra A, Kumar S, Green B, Geddes K, Pezo RC, Navarre WW, Milosevic M, Wilson BC, Girardin SE, Wolever TMS, Edelmann W, Guttman DS, Philpott DJ, Martin A. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 2014;158(2):288-299. doi: 10.1016/j.cell.2014.04.051.

Read More

Wolever TMS, Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate. Diabetes Care 1998;21:1612-18.

Read More
Pharmacokinetics

There are various methods for determining bioavailability and bioequivalency, depending on a product’s intended use. At INQUIS Clinical Research, our research team is well-equipped to address the pharmacokinetics involved with determining absorption. We are also experienced in examining physiological effects that can be used to demonstrate equivalency.

Contact us to learn how we can help you achieve your clinical research objectives.

Publications

Kinnear T, Wolever TMS, Murphy AM, Sullivan JA, Liu Q, Bizimungu B. Kinnear T, Wolever TMS, Murphy AM, Sullivan JA, Liu Q, Bizimungu B. Kinnear T, Wolever TMS, Murphy AM, Sullivan JA, Liu Q, Bizimungu B. Effect of preparation method on the glycaemic index of novel potato clones. Food Funct 2011;2:438-44.

Read More

Grysman A, Wolever TMS, Carlson T. Effects of sucromalt on postprandial responses in humans. Eur J Clin Nutr 2008;62:1364-71.

Read More

Wolever TMS, Robb PA. Effect of guar, pectin, psyllium, soy polysaccharide and cellulose on breath hydrogen and methane in healthy subjects. Am J Gastroenterol 1992;87:305-10.

Read More
Claims Support

At INQUIS Clinical Research, our research provides claims support for proteins, fibers, sweeteners, and NHPs (Natural Health Products).  Our research helps create a master file for NHP submission, supports health claims, and aids in product development to determine whether the examined ingredient has the intended physiological effect.

Contact us to learn how we can help you achieve your clinical research objectives.

Publications

Vuksan V, Whitham D, Sievenpiper JL, Jenkins AL, Rogovik AL, Bazinet RP, Vidgen E, Hanna A. Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial. Diabetes Care 2007;30(11):2804-10.

Read More

Jenkins AL, Kacinik V, Lyon M, Wolever TMS. Effect of adding the novel fiber, PGX®, to commonly consumed foods on glycemic response, glycemic index and GRIP: a simple and effective strategy for reducing post prandial blood glucose levels – a randomized, controlled trial. Nutr J 2010;9:58.

Read More

Jenkins AL, Kacinik V, Lyon MR, Wolever TMS. Reduction of postprandial glycemia by the novel viscous polysaccharide PGX®, in a dose-dependent manner, independent of food form. J Am Col Nutr 2010;29:92-98.

Read More
Bioavailability & Bioequivalency

There are various methods for determining bioavailability and bioequivalency, depending on a product’s intended use.  At INQUIS Clinical Research, our research team is well-equipped to address the pharmacokinetics involved with determining absorption.  We are also experienced in examining physiological effects that can be used to demonstrate equivalency.

Contact us to learn how we can help you achieve your clinical research objectives.

Publications

Jenkins AL, Kacinik V, Lyon M, Wolever TMS. Effect of adding the novel fiber, PGX®, to commonly consumed foods on glycemic response, glycemic index and GRIP: a simple and effective strategy for reducing post prandial blood glucose levels – a randomized, controlled trial. Nutr J. 2010 Nov 22;9:58.

Read More

Nutr J 2010;9:58.Vuksan V, Whitham D, Sievenpiper JL, Jenkins AL, Rogovik AL, Bazinet RP, Vidgen E, Hanna A. Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial.Diabetes Care 2007;30(11):2804-10.

Read More
Services

INQUIS Clinical Research offers a complete suite of services to help you structure your trial from end to end. We ensure you receive a custom-designed program that covers every aspect of your research needs seamlessly from beginning to end. We can partner as intensively as needed for clients who require our expertise with only some aspects of their clinical trial.

Features of our clinical trial services include:

Expertise
Expertise
Protocol Development
Expertise
Expertise
Ethics Submission
Expertise
Expertise
Recruitment
Expertise
Expertise
Trial Execution
Expertise
Expertise
Clinical Trial Management
Expertise
Expertise
Biological Sample Analysis
Expertise
Expertise
Biostatistics Calculation
Expertise
Expertise
Publication
Expertise
Expertise
SR&ED Preparation
Featured Clients
Contact Us Today
How can we help you achieve your research objectives?
  • This field is for validation purposes and should be left unchanged.